Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 2 |
| Report Guidance | 6 | 1 |
| Clinical Trials by Region | 7 | 9 |
| Clinical Trials and Average Enrollment by Country | 8 | 3 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 11 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 12 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 13 | 1 |
| Top Five Countries Contributing to Clinical Trials in Middle East and Africa | 14 | 1 |
| Top Five Countries Contributing to Clinical Trials in Central and South America | 15 | 1 |
| Clinical Trials by G7 Countries: Proportion of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) to Cardiovascular Clinical Trials | 16 | 2 |
| Clinical Trials by Phase in G7 Countries | 18 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 19 | 1 |
| Clinical Trials by E7 Countries: Proportion of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) to Cardiovascular Clinical Trials | 20 | 2 |
| Clinical Trials by Phase in E7 Countries | 22 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 23 | 1 |
| Clinical Trials by Phase | 24 | 2 |
| In Progress Trials by Phase | 25 | 1 |
| Clinical Trials by Trial Status | 26 | 1 |
| Clinical Trials by End Point Status | 27 | 1 |
| Subjects Recruited Over a Period of Time | 28 | 1 |
| Clinical Trials by Sponsor Type | 29 | 1 |
| Prominent Sponsors | 30 | 4 |
| Top Companies Participating in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics Clinical Trials | 32 | 2 |
| Prominent Drugs | 34 | 1 |
| Latest Clinical Trials News on Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) | 35 | 2 |
| Oct 04, 2016: AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease | 35 | 1 |
| Sep 29, 2016: Low levels of endogenous anti-PC identified as a novel risk factor for vein bypass graft failure and cardiovascular complications in PAD patients | 35 | 1 |
| Sep 28, 2016: Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS | 36 | 1 |
| Aug 11, 2016: Athera Biotechnologies completes First-in-Patient Study with New Antibody Against Immunovascular Disease | 36 | 1 |
| Clinical Trial Profile Snapshots | 37 | 233 |
| Appendix | 270 | 3 |
| Abbreviations | 270 | 1 |
| Definitions | 270 | 1 |
| Research Methodology | 271 | 1 |
| Secondary Research | 271 | 1 |
| About GlobalData | 272 | 1 |
| Contact Us | 272 | 1 |
| Disclaimer | 272 | 1 |
| Source | 273 | 1 |
